Therapeutic effect of transarterial chemoembolization combined with apatinib on patients with advanced hepatocellular carcinoma
10.3969/j.issn.1000-8179.2017.17.816
- VernacularTitle:肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌疗效评价
- Author:
YANG ZERAN
1
;
SU TIANHAO
;
YU JIAN'AN
;
CHEN GUANG
;
XIAO GUOWEN
;
JIN LONG
Author Information
1. 首都医科大学附属北京友谊医院放射介入科 北京市100032
- Keywords:
hepatocellular carcinoma;
transarterial chemoembolization;
targeted therapy;
apatinib
- From:
Chinese Journal of Clinical Oncology
2017;44(17):880-885
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the therapeutic effect of transarterial chemoembolization (TACE) combined with apatinib on pa-tients with advanced hepatocellular carcinoma (HCC). Methods:Twenty-one patients were treated with TACE combined with 250 mg of apatinib once a day. Disease classification was assessed by investigators using the modified Response Evaluation Criteria in Solid Tu-mors (mRECIST). The evaluation period was 28 days. Results:The therapeutic effects were classified as follows:3 patients (14.3%) had complete response, 6 patients (28.6%) had partial response, 5 patients (23.8%) had stable disease, and 2 patients (9.5%) had progres-sive disease. The disease control rate was 61.9%, and the objective response rate was 38.1%. In patients, the most frequent adverse events were fatigue (94.4%), anorexia (23.8%), diarrhea (19.0%), hypertension (19.0%), and hand-foot syndrome (19.0%). Conclusion:The short-term therapeutic effect revealed that the combination of TACE and apatinib could be a promising treatment for patients with advanced HCC. Adverse events should be closely monitored and provided with active management.
